All News

Jodi Taraba, PharmD, MS, BCOP, offers insights on the benefits of involving oncology pharmacists in clinical trial research to advance treatment and care for patients with cancer.

Clinical trials are using AI to handle large and complex volumes of data to develop oncology, cardiovascular, and neurologic compounds and to integrate molecular and imaging data.

Combination treatment of sotorasib plus panitumumab prolongs progression-free survival in those with metastatic colorectal cancer and the KRAS G12C mutation.

Fertility pharmacists understand the importance of education, awareness, and support women need to discover in navigating the complexities of fertility.

The incident highlights the benefits of out-of-court settlements in civil cases

Data have shown the potential for the therapy to treat several new conditions.

Tune into this episode of “Public Health Matters” to hear Dr. Kate Gainer’s journey in state pharmacy association and how advocacy and legislative initiatives can benefit pharmacists.

A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.

According to the investigators, these findings support the investigation of rilzabrutinib in patients with asthma in a phase 3 trial program.

The pharmaceutical landscape faces challenges with drug serialization, including data discrepancies and potential shortages, but technology emerges as a beacon of hope for the industry.

Experts emphasize the importance of awareness when using social media and make suggestions on how to combat the spread of misinformation and conspiracy theories.

The results showed that during a 1-month hospital stay, 13% of individuals who experienced RSV-associated acute respiratory failure died.

Smoking increases exposure to carbon monoxide, and this may be associated with better clinical response to autophagy inhibitors.

Test your knowledge of pharmacy with a quiz in collaboration with PTCE.

Inavolisib was submitted to the FDA for review as a first-line treatment for advanced HR-positive, HER2-negative PIK3CA-mutated breast cancer.

The results showed that individuals treated with milvexian had a prolonged aPTT in a dose-dependent manner with limited effects of PT.

Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.

Researchers from the University of Leipzig Medical Center identify multiple biomarkers associated with the success of CAR T cell therapy in relapsed multiple myeloma.

New research reveals the potential of community pharmacists in minor ailment treatment, allowing for diversified patient care during growing health care professional shortages.

The primary outcome was a 90-day incidence of mortality or liver transplant for individuals who received larsucosterol, compared to the placebo group.

Patricia Gutierrez, PharmD, BCACP, CDE, aims to combat the challenges in culturally competent care with knowledge and love for her community and patients.

Aligning community pharmacy interventions with top-down findings, payers’ population health priorities, and identified unmet needs can help develop a sustainable pathway.

As value-based health care models become more widespread, these types of interventions will be important to demonstrate the value of pharmacist-embedded HSSPs.

Results from the INCREASE study shed light on the value of the pharmacist in medication therapy management.

Aflibercept-jbvf (Yesafili; Biocon Biologics) and aflibercept-yszy (Opuviz; Biogen, Samsung Bioepis) are the first interchangeable biosimilars to aflibercept (Eylea; Regeneron).

Belimumab (Benlysta; GSK) is a B-lymphocyte stimulator-specific inhibiting monoclonal antibody.

In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.

Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.